GlassScriptPhysician profile
Aijaz H Turk
NPI 1689636367
$3,014.81
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $218 · 2021: $358 · 2022: $519 · 2023: $558 · 2024: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $19.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.33 |
| Education | $19.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $625.16 | 2019-2024 | Epclusa, Livdelzi |
| Abbvie INC. | $499.83 | 2019-2024 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $344.46 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $197.55 | 2019-2024 | Stelara |
| Pfizer INC. | $197.04 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.58 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $116.59 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Madrigal Pharmaceuticals | $116.08 | 2024 | Rezdiffra, Resmetirom |
| Ucb, INC. | $102.46 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $100.04 | 2024 | Monoferric |
| Janssen Scientific Affairs, LLC | $84.47 | 2020-2021 | |
| Lilly USA, LLC | $82.32 | 2024 | Omvoh |
| Celgene Corporation | $71.66 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $61.79 | 2022-2024 | Ocaliva |
| Axonics, INC. | $29.80 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $29.28 | 2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $28.13 | 2024 | Dupixent |
| Alnylam Pharmaceuticals INC. | $26.20 | 2021 | |
| Nestle Healthcare Nutrition INC. | $25.25 | 2021-2022 | |
| Celltrion USA INC. | $19.40 | 2024 | Zymfentra |
| Shionogi INC | $19.22 | 2019 | |
| Genzyme Corporation | $18.19 | 2023 | |
| Daiichi Sankyo INC. | $14.83 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aijaz Turk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.